Freestone Grove Partners LP Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Freestone Grove Partners LP acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 226,238 shares of the medical research company’s stock, valued at approximately $113,427,000. Thermo Fisher Scientific accounts for about 0.7% of Freestone Grove Partners LP’s investment portfolio, making the stock its 20th biggest position.

Other institutional investors also recently bought and sold shares of the company. Caisse de depot et placement du Quebec acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $105,280,000. Sculptor Capital LP acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $20,556,000. Man Group plc purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at approximately $97,845,000. Western Wealth Management LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at approximately $654,000. Finally, First Bancorp Inc ME purchased a new position in Thermo Fisher Scientific in the second quarter worth approximately $48,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Up 1.0%

TMO opened at $634.48 on Thursday. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $647.00. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The business has a fifty day simple moving average of $552.22 and a 200-day simple moving average of $510.70. The firm has a market cap of $234.60 billion, a P/E ratio of 34.13, a P/E/G ratio of 2.56 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the prior year, the company earned $4.28 EPS. Thermo Fisher Scientific’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $77,982,284.75. The trade was a 7.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the sale, the vice president owned 14,784 shares in the company, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on TMO shares. Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a research report on Wednesday, August 5th. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their price objective for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price on the stock. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They set a “market perform” rating and a $520.00 target price for the company. Finally, Royal Bank Of Canada boosted their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research note on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.